Charlene S Lee, MD
Hematology/Oncology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 9 carriers
- Office
- 1
Offices
1 location
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
32 plans · 9 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lee’s office at (408) 923-3388 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A128450 · Current
Licensed to practise in California · since 2014 · expires 2027-06-30 · St. George'S University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$196,964
Medicare paid this office $196,964 for 310 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 190 | $47,455 | $118 |
| Short return visit (20+ min) | 189 | $26,728 | $79 |
| Administration of chemotherapy into vein, 1 hour or less | 21 | $23,904 | $139 |
| New patient visit (60+ min) | 74 | $14,463 | $195 |
| Injection of additional new drug or substance into vein | 27 | $5,838 | $16 |
See all 12 services
| Return visit (30+ min) | 190 | $47,455 | $118 |
| Short return visit (20+ min) | 189 | $26,728 | $79 |
| Administration of chemotherapy into vein, 1 hour or less | 21 | $23,904 | $139 |
| New patient visit (60+ min) | 74 | $14,463 | $195 |
| Injection of additional new drug or substance into vein | 27 | $5,838 | $16 |
| New patient visit (45+ min) | 37 | $5,494 | $148 |
| Administration of chemotherapy into vein, each additional hour | 12 | $2,263 | $29 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 12 | $1,988 | $166 |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $446 | None |
| Infusion, normal saline solution, 250 cc | 32 | $360 | None |
| Insertion of needle into vein for collection of blood sample | 30 | $311 | $6 |
| Injection, diphenhydramine hcl, up to 50 mg | 21 | $115 | None |
Who their Medicare patients are
310 Original Medicare patients in 2024. Average age 77 · Under 65 5% · 85 and older 20% · Women 60% · Also on Medicaid 65% · Health risk score 1.86. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 49% · Cancer 44% · Chronic kidney disease 39% · Coronary heart disease 27% · Heart failure 16% · COPD 16% · Atrial fibrillation 14% · Dementia 10% · Depression 9% · Stroke 5%.
The office billed $444,693, Medicare allowed $257,272 and paid $196,964; for 55,832 services of 49 kinds; $20,826 of it was for drugs given in the office and $176,138 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 310 | 55,832 | 77 | 1.86 | $444,693 | $196,964 |
| 2023 | 310 | 63,528 | 76 | 1.98 | $436,054 | $190,591 |
| 2022 | 283 | 60,680 | 76 | 1.86 | $381,641 | $170,216 |
| 2021 | 186 | 665 | 77 | 1.87 | $81,893 | $47,036 |
| 2020 | 210 | 637 | 75 | 2.15 | $87,617 | $48,332 |
| 2019 | 206 | 8,173 | 76 | 2.09 | $103,803 | $61,693 |
| 2018 | 230 | 16,866 | 76 | 2.33 | $174,690 | $99,517 |
| 2017 | 39 | 193 | 77 | 1.19 | $11,894 | $7,432 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Short return visit (20+ min) | 218 | $43,792 | $80 |
| Administration of chemotherapy into vein using push technique | 13 | $32,743 | $109 |
| Return visit (30+ min) | 105 | $18,792 | $120 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $14,326 | $140 |
| New patient visit (60+ min) | 70 | $14,250 | $204 |
| Injection of additional new drug or substance into vein | 30 | $6,500 | $16 |
| Administration of additional new drug or substance into vein using push technique | 14 | $3,960 | $57 |
| New patient visit (45+ min) | 25 | $3,583 | $143 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,443 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,188 | $156 |
| Administration of chemotherapy into vein, each additional hour | 12 | $1,496 | $29 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,355 | $71 |
| Injection, ondansetron hydrochloride, per 1 mg | 30 | $524 | None |
| Infusion, normal saline solution, 250 cc | 33 | $300 | None |
| Insertion of needle into vein for collection of blood sample | 18 | $98 | $5 |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $86 | None |
2022: 13 services
| Administration of chemotherapy into vein using push technique | 11 | $38,943 | $113 |
| Short return visit (20+ min) | 206 | $36,267 | $84 |
| Administration of chemotherapy into vein, 1 hour or less | 16 | $12,155 | $148 |
| Return visit (30+ min) | 70 | $11,479 | $117 |
| New patient visit (60+ min) | 42 | $8,586 | $204 |
| Injection of additional new drug or substance into vein | 26 | $7,094 | $17 |
| New patient visit (45+ min) | 40 | $6,307 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,672 | $178 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,542 | $121 |
| Injection, ondansetron hydrochloride, per 1 mg | 26 | $462 | None |
| Infusion, normal saline solution, 250 cc | 29 | $299 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 19 | $68 | None |
| Insertion of needle into vein for collection of blood sample | 15 | $53 | $3 |
2021: 6 services
| Short return visit (20+ min) | 136 | $24,678 | $83 |
| New patient visit (45+ min) | 35 | $5,312 | $152 |
| New patient visit (60+ min) | 22 | $4,660 | $212 |
| Return visit (30+ min) | 21 | $3,384 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $2,108 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,248 | $66 |
2020: 9 services
| Short return visit (20+ min) | 142 | $21,847 | $63 |
| New patient visit (60+ min) | 43 | $8,177 | $190 |
| New patient visit (45+ min) | 26 | $3,969 | $153 |
| Return visit (30+ min) | 32 | $3,547 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,532 | $186 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $3,016 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,530 | $67 |
| Short return visit | 13 | $627 | $45 |
| Insertion of needle into vein for collection of blood sample | 14 | $48 | $3 |
2019: 9 services
| Short return visit (20+ min) | 135 | $20,438 | $68 |
| New patient visit (60+ min) | 44 | $8,245 | $187 |
| New patient visit (45+ min) | 30 | $4,466 | $149 |
| Return visit (30+ min) | 32 | $3,600 | $100 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,713 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,602 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,439 | $122 |
| Short return visit | 13 | $613 | $44 |
| Insertion of needle into vein for collection of blood sample | 18 | $59 | $3 |
2018: 16 services
| Short return visit (20+ min) | 139 | $22,875 | $69 |
| New patient visit (60+ min) | 63 | $12,058 | $191 |
| New patient visit (45+ min) | 55 | $7,948 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,640 | $182 |
| Return visit (30+ min) | 39 | $4,589 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 39 | $4,576 | $65 |
| Injection of additional new drug or substance into vein | 14 | $2,602 | $18 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,444 | $122 |
| Biopsy of bone marrow | 13 | $2,161 | $154 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,437 | $90 |
| Short return visit | 11 | $512 | $43 |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $122 | None |
| Insertion of needle into vein for collection of blood sample | 21 | $85 | $3 |
| Infusion, normal saline solution, 250 cc | 15 | $64 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $21 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 11 | $5 | None |
2017: 2 services
| New patient visit (60+ min) | 11 | $2,093 | $190 |
| Short return visit (20+ min) | 13 | $900 | $69 |
Medicaid work
$96 in 2023
Medicaid paid $96 for 75 billed services this clinician did in 2023, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 75 | $96 |
| 2023 | 75 | 1 | 21 | $96 |
| 2022 | 289 | 1 | 39 | $24 |
| 2021 | 438 | 2 | 44 | $32 |
| 2020 | 280 | 1 | 25 | $72 |
| 2019 | 121 | 1 | 21 | $0 |
| 2018 | 44 | 1 | 16 | $0 |
See the largest Medicaid services in earlier years
2022
| Short return visit (20+ min) | 289 | $24 |
2021
| Short return visit (20+ min) | 423 | $32 |
| New patient visit (45+ min) | 15 | $0 |
2020
| Short return visit (20+ min) | 280 | $72 |
2019
| Short return visit (20+ min) | 121 | $0 |
2018
| Short return visit (20+ min) | 44 | $0 |
Drugs they prescribed that Part D paid
$7,128,028
Pharmacies billed $7,128,028 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (74 of 1,962) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
1,437 generic and fewer than 11 brand-name prescriptions · $7,128,028 in drug cost · 35 antibiotic prescriptions to 24 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 102 | $1,607,396 | $15,759 |
| Promacta | 45 | $737,497 | $16,389 |
| Imbruvica | 38 | $626,768 | $16,494 |
| Xtandi | 42 | $556,640 | $13,253 |
| Zejula | 23 | $487,825 | $21,210 |
See all 44 drugs
| Tagrisso | 102 | $1,607,396 | $15,759 |
| Promacta | 45 | $737,497 | $16,389 |
| Imbruvica | 38 | $626,768 | $16,494 |
| Xtandi | 42 | $556,640 | $13,253 |
| Zejula | 23 | $487,825 | $21,210 |
| Jakafi | 34 | $450,003 | $13,235 |
| Cabometyx | 16 | $429,270 | $26,829 |
| Ibrance | 23 | $358,775 | $15,599 |
| Brukinsa | 21 | $269,504 | $12,834 |
| Lenalidomide | 19 | $222,249 | $11,697 |
| Krazati | 11 | $128,154 | $11,650 |
| Eliquis | 41 | $31,776 | $775 |
| Imatinib Mesylate | 18 | $30,272 | $1,682 |
| Xarelto | 18 | $24,952 | $1,386 |
| Exemestane | 30 | $7,420 | $247 |
| Cyclosporine Modified | 24 | $4,969 | $207 |
| Tenofovir Disoproxil | 12 | $3,763 | $314 |
| Anastrozole | 197 | $3,230 | $16 |
| Entecavir | 14 | $2,524 | $180 |
| Ondansetron Odt | 119 | $2,263 | $19 |
| Tamoxifen Citrate | 50 | $1,883 | $38 |
| Deferasirox | 15 | $1,694 | $113 |
| Danazol | 16 | $1,593 | $100 |
| Montelukast | 113 | $1,438 | $13 |
| Hydroxyurea | 91 | $1,268 | $14 |
| Raloxifene | 28 | $1,034 | $37 |
| Famotidine | 97 | $851 | $9 |
| Letrozole | 21 | $587 | $28 |
| Loperamide | 18 | $515 | $29 |
| Gabapentin | 34 | $477 | $14 |
| Hydrocodone-Acetaminophen | 22 | $452 | $21 |
| Mirtazapine | 25 | $421 | $17 |
| Triamcinolone Acetonide | 26 | $407 | $16 |
| Dexamethasone | 29 | $287 | $10 |
| Tramadol | 37 | $161 | $4 |
| Allopurinol | 26 | $151 | $6 |
| Omeprazole | 14 | $149 | $11 |
| Metoclopramide | 16 | $149 | $9 |
| Alendronate | 22 | $142 | $6 |
| Hydrocortisone | 20 | $115 | $6 |
| Folic Acid | 17 | $79 | $5 |
| Prednisone | 27 | $78 | $3 |
| Warfarin | 11 | $75 | $7 |
| Azithromycin | 13 | $46 | $4 |
Year by year
| 2024 | 1,962 | 380 | 4% (74) | None | $7,128,028 |
| 2023 | 2,005 | 398 | 4% (82) | None | $5,456,278 |
| 2022 | 1,630 | 343 | 6% (101) | None | $3,289,660 |
| 2021 | 1,890 | 330 | 2% (44) | 20% | $3,825,579 |
| 2020 | 2,106 | 340 | 2% (51) | 17% | $3,225,579 |
| 2019 | 1,346 | 280 | 3% (43) | 16% | $2,270,936 |
| 2018 | 1,232 | 223 | 4% (51) | 21% | $2,123,438 |
| 2017 | 212 | 79 | 8% (17) | 26% | $375,742 |
| 2016 | 79 | 25 | 23% (18) | 30% | $134,161 |
| 2015 | 134 | 50 | 11% (15) | None | $93,875 |
| 2014 | 531 | 68 | 2% (11) | None | $56,319 |
| 2013 | 791 | 86 | 2% (13) | 16% | $38,438 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 42 drugs
| Tagrisso | 71 | $1,266,890 | $17,844 |
| Jakafi | 30 | $470,415 | $15,680 |
| Revlimid | 30 | $446,326 | $14,878 |
| Imbruvica | 22 | $360,619 | $16,392 |
| Ibrance | 20 | $326,241 | $16,312 |
| Xtandi | 22 | $321,290 | $14,604 |
| Cabometyx | 11 | $317,741 | $28,886 |
| Promacta | 17 | $272,103 | $16,006 |
| Sprycel | 11 | $203,766 | $18,524 |
| Verzenio | 17 | $102,203 | $6,012 |
| Imatinib Mesylate | 56 | $102,010 | $1,822 |
| Xarelto | 42 | $52,931 | $1,260 |
| Eliquis | 42 | $34,919 | $831 |
| Deferasirox | 16 | $22,358 | $1,397 |
| Exemestane | 42 | $15,193 | $362 |
| Anastrozole | 210 | $9,650 | $46 |
| Danazol | 23 | $8,744 | $380 |
| Tenofovir Disoproxil | 13 | $6,442 | $496 |
| Cyclosporine Modified | 35 | $5,289 | $151 |
| Ondansetron Odt | 159 | $5,230 | $33 |
| Raloxifene | 42 | $4,992 | $119 |
| Tamoxifen Citrate | 45 | $2,573 | $57 |
| Hydroxyurea | 81 | $2,189 | $27 |
| Montelukast | 85 | $2,001 | $24 |
| Famotidine | 82 | $1,600 | $20 |
| Gabapentin | 75 | $1,327 | $18 |
| Dexamethasone | 48 | $1,009 | $21 |
| Hydrocodone-Acetaminophen | 36 | $852 | $24 |
| Mirtazapine | 32 | $829 | $26 |
| Loperamide | 17 | $813 | $48 |
| Letrozole | 19 | $761 | $40 |
| Alendronate | 30 | $679 | $23 |
| Triamcinolone Acetonide | 18 | $628 | $35 |
| Tramadol | 44 | $609 | $14 |
| Albuterol Sulfate Hfa | 15 | $501 | $33 |
| Allopurinol | 28 | $471 | $17 |
| Warfarin | 11 | $410 | $37 |
| Metoclopramide | 16 | $297 | $19 |
| Omeprazole | 28 | $286 | $10 |
| Prednisone | 29 | $177 | $6 |
| Hydrocortisone | 14 | $166 | $12 |
| Azithromycin | 17 | $96 | $6 |
2022: 37 drugs
| Tagrisso | 50 | $822,094 | $16,442 |
| Revlimid | 25 | $437,190 | $17,488 |
| Imbruvica | 22 | $340,577 | $15,481 |
| Lynparza | 13 | $188,176 | $14,475 |
| Promacta | 13 | $124,336 | $9,564 |
| Verzenio | 13 | $117,069 | $9,005 |
| Jakafi | 12 | $114,218 | $9,518 |
| Imatinib Mesylate | 62 | $87,828 | $1,417 |
| Xarelto | 35 | $40,437 | $1,155 |
| Eliquis | 45 | $29,255 | $650 |
| Vemlidy | 11 | $15,419 | $1,402 |
| Exemestane | 28 | $12,459 | $445 |
| Raloxifene | 35 | $6,533 | $187 |
| Anastrozole | 142 | $4,418 | $31 |
| Danazol | 22 | $3,819 | $174 |
| Ondansetron Odt | 84 | $2,331 | $28 |
| Cyclosporine Modified | 15 | $2,186 | $146 |
| Montelukast | 78 | $2,118 | $27 |
| Dexamethasone | 75 | $1,858 | $25 |
| Hydroxyurea | 85 | $1,684 | $20 |
| Tamoxifen Citrate | 39 | $1,582 | $41 |
| Famotidine | 80 | $1,444 | $18 |
| Loperamide | 18 | $1,011 | $56 |
| Mirtazapine | 26 | $902 | $35 |
| Hydrocodone-Acetaminophen | 29 | $821 | $28 |
| Gabapentin | 67 | $763 | $11 |
| Letrozole | 13 | $485 | $37 |
| Omeprazole | 27 | $312 | $12 |
| Alendronate | 23 | $308 | $13 |
| Tramadol | 57 | $284 | $5 |
| Hydrocortisone | 15 | $276 | $18 |
| Azathioprine | 13 | $251 | $19 |
| Allopurinol | 18 | $236 | $13 |
| Ondansetron | 14 | $169 | $12 |
| Amlodipine Besylate | 13 | $130 | $10 |
| Folic Acid | 16 | $95 | $6 |
| Prednisone | 12 | $65 | $5 |
2021: 43 drugs
| Tagrisso | 67 | $1,083,311 | $16,169 |
| Revlimid | 36 | $590,974 | $16,416 |
| Imbruvica | 23 | $325,916 | $14,170 |
| Lynparza | 20 | $292,320 | $14,616 |
| Xtandi | 23 | $280,619 | $12,201 |
| Jakafi | 16 | $205,588 | $12,849 |
| Ibrance | 11 | $159,664 | $14,515 |
| Promacta | 19 | $157,308 | $8,279 |
| Imatinib Mesylate | 43 | $51,181 | $1,190 |
| Xarelto | 39 | $27,997 | $718 |
| Eliquis | 28 | $18,342 | $655 |
| Exemestane | 34 | $7,301 | $215 |
| Anastrozole | 252 | $4,942 | $20 |
| Danazol | 22 | $4,899 | $223 |
| Deferasirox | 12 | $4,313 | $359 |
| Raloxifene | 45 | $4,255 | $95 |
| Tenofovir Disoproxil | 19 | $3,490 | $184 |
| Febuxostat | 13 | $2,622 | $202 |
| Cyclosporine Modified | 14 | $2,042 | $146 |
| Tamoxifen Citrate | 64 | $1,836 | $29 |
| Dexamethasone | 71 | $1,653 | $23 |
| Ondansetron Odt | 81 | $1,607 | $20 |
| Hydroxyurea | 93 | $1,477 | $16 |
| Famotidine | 119 | $1,046 | $9 |
| Montelukast | 120 | $999 | $8 |
| Letrozole | 16 | $814 | $51 |
| Azathioprine | 20 | $629 | $31 |
| Gabapentin | 46 | $555 | $12 |
| Mirtazapine | 15 | $485 | $32 |
| Loperamide | 13 | $460 | $35 |
| Hydrocodone-Acetaminophen | 20 | $404 | $20 |
| Levothyroxine | 19 | $307 | $16 |
| Omeprazole | 17 | $277 | $16 |
| Alendronate | 33 | $248 | $8 |
| Prednisone | 34 | $237 | $7 |
| Acyclovir | 11 | $225 | $20 |
| Promethazine-Codeine | 11 | $208 | $19 |
| Allopurinol | 18 | $150 | $8 |
| Zolpidem | 17 | $139 | $8 |
| Tramadol | 16 | $117 | $7 |
| Furosemide | 17 | $96 | $6 |
| Hydrocortisone | 12 | $76 | $6 |
| Folic Acid | 24 | $57 | $2 |
2020: 42 drugs
| Tagrisso | 45 | $708,428 | $15,743 |
| Revlimid | 39 | $604,593 | $15,502 |
| Cabometyx | 13 | $282,952 | $21,766 |
| Lynparza | 16 | $217,251 | $13,578 |
| Imbruvica | 16 | $207,633 | $12,977 |
| Xtandi | 17 | $204,287 | $12,017 |
| Promacta | 20 | $130,467 | $6,523 |
| Jakafi | 13 | $128,672 | $9,898 |
| Imatinib Mesylate | 47 | $43,997 | $936 |
| Xarelto | 48 | $31,700 | $660 |
| Eliquis | 32 | $15,056 | $471 |
| Exemestane | 29 | $7,807 | $269 |
| Raloxifene | 58 | $7,238 | $125 |
| Tenofovir Disoproxil | 27 | $4,427 | $164 |
| Anastrozole | 269 | $3,755 | $14 |
| Danazol | 18 | $3,063 | $170 |
| Tamoxifen Citrate | 99 | $2,586 | $26 |
| Dexamethasone | 99 | $1,895 | $19 |
| Cyclosporine Modified | 18 | $1,484 | $82 |
| Montelukast | 149 | $1,236 | $8 |
| Letrozole | 19 | $1,119 | $59 |
| Hydroxyurea | 65 | $1,055 | $16 |
| Famotidine | 125 | $979 | $8 |
| Triamcinolone Acetonide | 14 | $971 | $69 |
| Ondansetron | 60 | $830 | $14 |
| Ondansetron Odt | 35 | $767 | $22 |
| Azathioprine | 17 | $744 | $44 |
| Mirtazapine | 43 | $673 | $16 |
| Gabapentin | 63 | $644 | $10 |
| Loperamide | 18 | $567 | $31 |
| Prednisone | 55 | $321 | $6 |
| Alendronate | 52 | $314 | $6 |
| Hydrocodone-Acetaminophen | 18 | $287 | $16 |
| Allopurinol | 30 | $285 | $9 |
| Hydroxyzine | 12 | $268 | $22 |
| Zolpidem | 27 | $178 | $7 |
| Omeprazole | 23 | $159 | $7 |
| Furosemide | 15 | $121 | $8 |
| Tramadol | 24 | $93 | $4 |
| Hydrocortisone | 11 | $82 | $7 |
| Metoclopramide | 12 | $66 | $5 |
| Folic Acid | 12 | $41 | $3 |
2019: 30 drugs
| Revlimid | 22 | $389,982 | $17,726 |
| Cabometyx | 13 | $259,132 | $19,933 |
| Tagrisso | 16 | $242,349 | $15,147 |
| Nexavar | 15 | $201,557 | $13,437 |
| Xtandi | 12 | $142,801 | $11,900 |
| Iressa | 20 | $125,467 | $6,273 |
| Imatinib Mesylate | 27 | $43,472 | $1,610 |
| Xarelto | 25 | $14,070 | $563 |
| Exemestane | 39 | $8,962 | $230 |
| Eliquis | 15 | $7,090 | $473 |
| Raloxifene | 48 | $4,973 | $104 |
| Danazol | 20 | $3,848 | $192 |
| Anastrozole | 146 | $2,502 | $17 |
| Tamoxifen Citrate | 72 | $2,114 | $29 |
| Dexamethasone | 68 | $1,924 | $28 |
| Cyclosporine Modified | 18 | $1,005 | $56 |
| Ondansetron | 42 | $990 | $24 |
| Hydroxyurea | 59 | $881 | $15 |
| Montelukast | 89 | $842 | $9 |
| Mirtazapine | 28 | $744 | $27 |
| Famotidine | 86 | $536 | $6 |
| Gabapentin | 35 | $445 | $13 |
| Loperamide | 14 | $306 | $22 |
| Prednisone | 41 | $265 | $6 |
| Alendronate | 30 | $184 | $6 |
| Allopurinol | 15 | $157 | $10 |
| Tramadol | 24 | $96 | $4 |
| Omeprazole | 15 | $83 | $6 |
| Amlodipine Besylate | 19 | $83 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $33 | $3 |
2018: 31 drugs
| Revlimid | 28 | $485,989 | $17,357 |
| Nexavar | 17 | $267,475 | $15,734 |
| Cabometyx | 12 | $215,955 | $17,996 |
| Jakafi | 13 | $153,125 | $11,779 |
| Iressa | 17 | $132,622 | $7,801 |
| Xtandi | 11 | $125,406 | $11,401 |
| Danazol | 15 | $6,017 | $401 |
| Xarelto | 14 | $5,846 | $418 |
| Eliquis | 12 | $5,279 | $440 |
| Tenofovir Disoproxil | 20 | $4,966 | $248 |
| Dexamethasone | 72 | $1,536 | $21 |
| Anastrozole | 99 | $1,337 | $14 |
| Tamoxifen Citrate | 35 | $1,182 | $34 |
| Hydroxyurea | 34 | $1,007 | $30 |
| Montelukast | 120 | $936 | $8 |
| Ondansetron | 36 | $815 | $23 |
| Famotidine | 122 | $688 | $6 |
| Cyclosporine Modified | 11 | $623 | $57 |
| Hydrocodone-Acetaminophen | 21 | $458 | $22 |
| Potassium Chloride | 18 | $427 | $24 |
| Ivermectin | 12 | $426 | $36 |
| Ondansetron Odt | 14 | $388 | $28 |
| Mirtazapine | 20 | $334 | $17 |
| Allopurinol | 27 | $282 | $10 |
| Prednisone | 35 | $282 | $8 |
| Loperamide | 12 | $220 | $18 |
| Tramadol | 22 | $191 | $9 |
| Hydrocortisone | 16 | $145 | $9 |
| Alendronate | 21 | $105 | $5 |
| Zolpidem | 12 | $65 | $5 |
| Omeprazole | 11 | $58 | $5 |
2017: 2 drugs
| Ondansetron | 16 | $203 | $13 |
| Allopurinol | 11 | $123 | $11 |
2014: 9 drugs
| Lantus Solostar | 17 | $10,382 | $611 |
| Omeprazole | 38 | $667 | $18 |
| Pravastatin | 20 | $441 | $22 |
| Metformin | 44 | $235 | $5 |
| Amlodipine Besylate | 39 | $173 | $4 |
| Hydrochlorothiazide | 38 | $154 | $4 |
| Lisinopril | 33 | $135 | $4 |
| Isosorbide Mononitrate Er | 11 | $69 | $6 |
| Allopurinol | 13 | $48 | $4 |
2013: 21 drugs
| Lantus Solostar | 28 | $12,110 | $433 |
| Diovan | 13 | $2,096 | $161 |
| Nifedipine Er | 15 | $749 | $50 |
| Atorvastatin | 22 | $485 | $22 |
| Lisinopril | 81 | $404 | $5 |
| Metformin | 62 | $388 | $6 |
| Omeprazole | 17 | $349 | $21 |
| Amlodipine Besylate | 53 | $314 | $6 |
| Simvastatin | 26 | $224 | $9 |
| Alendronate | 21 | $189 | $9 |
| Ranitidine | 15 | $176 | $12 |
| Pravastatin | 13 | $171 | $13 |
| Clopidogrel | 15 | $162 | $11 |
| Hydrochlorothiazide | 38 | $141 | $4 |
| Levothyroxine | 16 | $135 | $8 |
| Glyburide | 11 | $123 | $11 |
| Furosemide | 13 | $113 | $9 |
| Lovastatin | 13 | $86 | $7 |
| Metoprolol | 17 | $77 | $5 |
| Atenolol | 16 | $57 | $4 |
| Allopurinol | 14 | $52 | $4 |
Money from drug and device companies
$3,714 in 2025
| 2025 | 35 | 143 | None | $3,714 |
| 2024 | 32 | 124 | None | $2,911 |
| 2023 | 25 | 73 | None | $1,875 |
| 2022 | 27 | 98 | None | $2,003 |
| 2021 | 23 | 47 | None | $1,047 |
| 2020 | 15 | 38 | None | $848 |
| 2019 | 16 | 53 | $2,300 | $4,510 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $588 | 21 payments
|
| Janssen Biotech | Rybrevant | $373 | 13 payments
|
| Novartis Pharmaceuticals | Kisqali | $254 | 10 payments
|
| BeOne Medicines USA | Tevimbra | $248 | 7 payments
|
| Merck Sharp & Dohme | Keytruda | $243 | 9 payments
|
| GlaxoSmithKline | Jemperli | $150 | 7 payments
|
See all 133 published payments
| Acrotech Biopharma | Meals · 2025-12-13 | None | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-11 | Opdivo | $16 |
| Novartis Pharmaceuticals | Meals · 2025-12-10 | Pluvicto | $27 |
| Novocure | Meals · 2025-12-10 | Optune Lua (Novottf-200t) | $46 |
| BeOne Medicines USA | Meals · 2025-12-08 | Brukinsa | $34 |
| BeOne Medicines USA | Meals · 2025-12-03 | Tevimbra | $32 |
| Abbvie | Meals · 2025-12-02 | Imbruvica | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-25 | Enhertu | $31 |
| Progenics Pharmaceuticals | Meals · 2025-11-19 | Pylarify | $23 |
| BeOne Medicines USA | Meals · 2025-11-12 | Brukinsa | $2 |
| BeOne Medicines USA | Meals · 2025-11-11 | Brukinsa | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-08 | None | $19 |
| PharmaEssentia USA | Meals · 2025-11-03 | Besremi | $27 |
| Coherus Oncology | Meals · 2025-10-30 | Loqtorzi | $25 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-28 | Eliquis | $26 |
| Astellas Pharma US | Meals · 2025-10-27 | Xtandi | $32 |
| Aveo Pharmaceuticals | Meals · 2025-10-23 | Fotivda | $27 |
| Novartis Pharmaceuticals | Meals · 2025-10-22 | Kisqali | $31 |
| Pfizer | Meals · 2025-10-20 | Ibrance | $23 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-16 | Imfinzi | $20 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-16 | Nubeqa | $24 |
| Novocure | Meals · 2025-10-14 | Optune Lua (Novottf-200t) | $17 |
| Merck Sharp & Dohme | Meals · 2025-10-02 | Keytruda | $22 |
| GlaxoSmithKline | Meals · 2025-10-01 | Ojjaara | $22 |
| Amgen | Meals · 2025-09-30 | Kyprolis | $27 |
| Merck Sharp & Dohme | Meals · 2025-09-25 | Keytruda | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-24 | Enhertu | $32 |
| Agios Pharmaceuticals | Meals · 2025-09-22 | Pyrukynd | $36 |
| Eisai | Meals · 2025-09-17 | Lenvima | $19 |
| Janssen Biotech | Meals · 2025-09-15 | Erleada | $24 |
| Janssen Biotech | Meals · 2025-09-15 | Erleada | $4 |
| Merck Sharp & Dohme | Meals · 2025-09-11 | Keytruda | $23 |
| Rigel Pharmaceuticals | Meals · 2025-09-08 | Tavalisse | $27 |
| GlaxoSmithKline | Meals · 2025-09-05 | Jemperli | $25 |
| Progenics Pharmaceuticals | Meals · 2025-09-03 | Pylarify | $26 |
| Merck Sharp & Dohme | Meals · 2025-08-28 | Keytruda | $27 |
| Novartis Pharmaceuticals | Meals · 2025-08-27 | Pluvicto | $17 |
| Novartis Pharmaceuticals | Meals · 2025-08-27 | Pluvicto | $8 |
| Janssen Biotech | Meals · 2025-08-25 | Rybrevant | $38 |
| Janssen Biotech | Meals · 2025-08-21 | Darzalex | $6 |
| Janssen Biotech | Meals · 2025-08-21 | Darzalex | $31 |
| Pfizer | Meals · 2025-08-13 | Xtandi | $35 |
| Genzyme | Meals · 2025-08-11 | Ayvakit | $30 |
| Kite Pharma | Meals · 2025-08-07 | Yescarta | $28 |
| Novocure | Meals · 2025-08-04 | Optune Lua (Novottf-200t) | $31 |
| Eisai | Meals · 2025-08-01 | Lenvima | $31 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-07-30 | Opdivo | $21 |
| Janssen Biotech | Meals · 2025-07-28 | Erleada | $34 |
| Astellas Pharma US | Meals · 2025-07-24 | Xtandi | $27 |
| Lilly USA | Meals · 2025-07-15 | None | $25 |
| Daiichi Sankyo | Meals · 2025-07-15 | Datroway | $30 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-09 | Imfinzi | $24 |
| Puma Biotechnology | Meals · 2025-07-09 | Nerlynx | $29 |
| Novartis Pharmaceuticals | Meals · 2025-07-02 | Kisqali | $36 |
| Gilead Sciences | Meals · 2025-06-25 | Trodelvy | $20 |
| BeOne Medicines USA | Meals · 2025-06-16 | Tevimbra | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-16 | None | $30 |
| Eisai | Meals · 2025-06-16 | Lenvima | $28 |
| Merck Sharp & Dohme | Meals · 2025-06-12 | Keytruda | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-09 | Enhertu | $14 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-09 | Enhertu | $17 |
| Array Biopharma | Meals · 2025-06-05 | Xalkori | $25 |
| GlaxoSmithKline | Meals · 2025-06-03 | Jemperli | $19 |
| Merck Sharp & Dohme | Meals · 2025-05-29 | Keytruda | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-28 | Calquence | $21 |
| Novocure | Meals · 2025-05-27 | Optune Lua (Novottf-200t) | $23 |
| Abbvie | Meals · 2025-05-21 | Elahere | $31 |
| Lilly USA | Meals · 2025-05-15 | Verzenio | $27 |
| Daiichi Sankyo | Meals · 2025-05-15 | Enhertu | $14 |
| Lilly USA | Meals · 2025-05-14 | Jaypirca | $31 |
| Rigel Pharmaceuticals | Meals · 2025-05-13 | Tavalisse | $34 |
| Janssen Biotech | Meals · 2025-05-12 | Rybrevant | $38 |
| BeOne Medicines USA | Meals · 2025-05-09 | Tevimbra | $10 |
| Merck Sharp & Dohme | Meals · 2025-05-08 | Keytruda | $25 |
| Progenics Pharmaceuticals | Meals · 2025-05-07 | Pylarify | $26 |
| PharmaEssentia USA | Meals · 2025-05-06 | Besremi | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-05 | Calquence | $26 |
| AstraZeneca Pharmaceuticals LP | Education · 2025-05-05 | None | $23 |
| Novartis Pharmaceuticals | Meals · 2025-05-01 | Pluvicto | $28 |
| Astellas Pharma US | Meals · 2025-04-30 | Vyloy | $20 |
| Sobi | Meals · 2025-04-29 | Vonjo | $37 |
| Sobi | Education · 2025-04-29 | None | $85 |
| GlaxoSmithKline | Meals · 2025-04-24 | Jemperli | $23 |
| BeOne Medicines USA | Meals · 2025-04-24 | Tevimbra | $118 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-24 | Advate | $23 |
| Abbvie | Meals · 2025-04-22 | Imbruvica | $21 |
| Deciphera Pharmaceuticals | Meals · 2025-04-22 | Qinlock | $34 |
| Legend Biotech USA | Meals · 2025-04-21 | Carvykti | $30 |
| Janssen Biotech | Meals · 2025-04-17 | Rybrevant | $4 |
| Janssen Biotech | Meals · 2025-04-17 | Rybrevant | $37 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-16 | Imfinzi | $31 |
| Janssen Biotech | Meals · 2025-04-15 | Erleada | $35 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-04-14 | Eliquis | $26 |
| Merck Sharp & Dohme | Meals · 2025-04-10 | Keytruda | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-09 | Enhertu | $35 |
| Aveo Pharmaceuticals | Meals · 2025-04-08 | Fotivda | $29 |
| Novartis Pharmaceuticals | Meals · 2025-04-07 | Pluvicto | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-07 | Tagrisso | $29 |
| Lilly USA | Meals · 2025-03-26 | Verzenio | $30 |
| GlaxoSmithKline | Meals · 2025-03-24 | Jemperli | $28 |
| Eisai | Meals · 2025-03-19 | Lenvima | $21 |
| PharmaEssentia USA | Meals · 2025-03-19 | Besremi | $31 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-03-13 | Nubeqa | $28 |
| Astellas Pharma US | Meals · 2025-03-12 | Xtandi | $25 |
| Legend Biotech USA | Meals · 2025-03-10 | Carvykti | $29 |
| Abbvie | Meals · 2025-03-06 | Elahere | $25 |
| Novartis Pharmaceuticals | Meals · 2025-03-05 | Pluvicto | $30 |
| Celgene | Meals · 2025-03-04 | Reblozyl | $25 |
| GlaxoSmithKline | Meals · 2025-03-04 | Jemperli | $16 |
| Astellas Pharma US | Meals · 2025-03-03 | Xtandi | $28 |
| Blueprint Medicines | Meals · 2025-02-27 | Ayvakit | $29 |
| Janssen Biotech | Meals · 2025-02-25 | Darzalex | $44 |
| Novocure | Meals · 2025-02-24 | Optune Lua (Novottf-200t) | $30 |
| Novartis Pharmaceuticals | Meals · 2025-02-20 | Kisqali | $34 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-13 | Imfinzi | $29 |
| Novartis Pharmaceuticals | Meals · 2025-02-11 | Kisqali | $34 |
| Progenics Pharmaceuticals | Meals · 2025-02-06 | Pylarify | $31 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-04 | Calquence | $30 |
| Janssen Biotech | Meals · 2025-02-03 | Rybrevant | $37 |
| Stemline Therapeutics | Meals · 2025-01-30 | Orserdu | $30 |
| Aveo Pharmaceuticals | Meals · 2025-01-28 | Fotivda | $29 |
| Coherus Oncology | Meals · 2025-01-27 | Loqtorzi | $39 |
| Merck Sharp & Dohme | Meals · 2025-01-23 | Keytruda | $28 |
| Rigel Pharmaceuticals | Meals · 2025-01-20 | Tavalisse | $39 |
| GlaxoSmithKline | Meals · 2025-01-17 | Jemperli | $17 |
| Janssen Biotech | Meals · 2025-01-16 | Darzalex | $41 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-16 | Enhertu | $33 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-15 | Tagrisso | $38 |
| Amgen | Meals · 2025-01-13 | Nplate | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-10 | Lynparza | $19 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-09 | Imfinzi | $29 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-01-09 | Tagrisso | $60 |
| Celgene | Meals · 2025-01-06 | Reblozyl | $22 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $2,911
| AstraZeneca Pharmaceuticals LP | Enhertu | $575 | 16 payments
|
| Astellas Pharma US | Vyloy | $270 | 8 payments
|
| Pfizer | Elrexfio | $265 | 23 payments
|
| Novartis Pharmaceuticals | Scemblix | $211 | 7 payments
|
| Janssen Biotech | Darzalex | $210 | 10 payments
|
| Coherus Biosciences | Udenyca | $147 | 4 payments
|
| Regeneron Healthcare Solutions | Libtayo | $97 | 3 payments
|
| Abbvie | Imbruvica | $96 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $86 | 3 payments
|
| Array Biopharma | Xalkori | $74 | 3 payments
|
| GlaxoSmithKline | Ojjaara | $73 | 3 payments
|
| Sobi | Vonjo | $67 | 2 payments
|
| Celgene | Reblozyl | $61 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $59 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $53 | 2 payments
|
| Sirtex Medical | Sir-Spheres Microspheres | $53 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $48 | 2 payments
|
| Daiichi Sankyo | Enhertu | $47 | 2 payments
|
| Taiho Oncology | Lonsurf | $36 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $36 | 1 payment
|
| EMD Serono | None | $34 | 1 payment
|
| Stemline Therapeutics | Orserdu | $34 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $34 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $33 | 1 payment
|
| Novocure | Optune Lua (Novottf-200t) | $32 | 1 payment
|
| Lilly USA | Verzenio | $30 | 1 payment
|
| PharmaEssentia USA | Besremi | $29 | 1 payment
|
| Genmab U.S. | Epkinly | $28 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| Tempus AI | None | $25 | 1 payment
|
| BeiGene USA | Tevimbra | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $20 | 1 payment
|
2023: $1,875
| AstraZeneca Pharmaceuticals LP | Imfinzi | $279 | 9 payments
|
| Merck Sharp & Dohme | Keytruda | $173 | 6 payments
|
| Janssen Biotech | Imbruvica | $168 | 3 payments
|
| Seagen | Adcetris | $162 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $150 | 12 payments
|
| Lilly USA | Verzenio | $143 | 8 payments
|
| Astellas Pharma US | Padcev | $102 | 2 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $95 | 1 payment
|
| Daiichi Sankyo | Enhertu | $74 | 3 payments
|
| Progenics Pharmaceuticals | Pylarify | $67 | 3 payments
|
| EMD Serono | Bavencio | $50 | 2 payments
|
| Novartis Pharmaceuticals | Pluvicto | $50 | 2 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $45 | 2 payments
|
| Celgene | Reblozyl | $40 | 2 payments
|
| Elekta | Elekta Unity | $34 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $31 | 1 payment
|
| Amgen | Nplate | $27 | 1 payment
|
| CTI BioPharma | Vonjo | $27 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $26 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $24 | 1 payment
|
| Genentech USA | Tecentriq | $23 | 1 payment
|
| Eisai | Lenvima | $23 | 1 payment
|
| Palette Life Sciences | None | $21 | 1 payment
|
| Pfizer | Inlyta | $20 | 1 payment
|
| Kite Pharma | None | $20 | 1 payment
|
2022: $2,003
| Janssen Biotech | Imbruvica | $317 | 10 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $239 | 11 payments
|
| Lilly USA | Verzenio | $154 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $150 | 12 payments
|
| Rigel Pharmaceuticals | Tavalisse | $149 | 2 payments
|
| Celgene | Pomalyst | $114 | 5 payments
|
| GlaxoSmithKline | Blenrep | $95 | 4 payments
|
| Amgen | Lumakras | $86 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $86 | 4 payments
|
| Seagen | Adcetris | $66 | 3 payments
|
| Kite Pharma | None | $59 | 2 payments
|
| Sobi | Doptelet | $54 | 2 payments
|
| Pfizer | Xalkori | $53 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $46 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $46 | 2 payments
|
| ADC Therapeutics America | None | $39 | 1 payment
|
| Puma Biotechnology | Nerlynx | $28 | 1 payment
|
| Incyte | Monjuvi | $26 | 1 payment
|
| Blueprint Medicines | Ayvakit | $26 | 1 payment
|
| Eisai | Lenvima | $25 | 1 payment
|
| Genentech USA | None | $24 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $22 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Clovis Oncology | Rubraca | $22 | 1 payment
|
| MorphoSys US | Monjuvi | $21 | 1 payment
|
| Astellas Pharma US | Padcev | $17 | 1 payment
|
| Gilead Sciences | Trodelvy | $16 | 1 payment
|
2021: $1,047
| Pfizer | Ibrance | $100 | 4 payments
|
| Seagen | Adcetris | $98 | 5 payments
|
| Lilly USA | Cyramza | $91 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $83 | 4 payments
|
| Novartis Pharmaceuticals | Lutathera | $81 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | None | $81 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $65 | 3 payments
|
| Janssen Biotech | Erleada | $56 | 2 payments
|
| Eisai | Lenvima | $41 | 2 payments
|
| Astellas Pharma US | Padcev | $38 | 2 payments
|
| Aveo Pharmaceuticals | Fotivda | $32 | 1 payment
|
| Blueprint Medicines | Gavreto | $32 | 1 payment
|
| Amgen | Nplate | $30 | 1 payment
|
| GlaxoSmithKline | Blenrep | $27 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $26 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $26 | 1 payment
|
| Puma Biotechnology | Nerlynx | $24 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $24 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $23 | 1 payment
|
| Clovis Oncology | Rubraca | $19 | 1 payment
|
| Array Biopharma | Braftovi | $18 | 1 payment
|
| Celgene | Inrebic | $16 | 1 payment
|
| Foundation Medicine | Foundationone | $15 | 1 payment
|
2020: $848
| Pfizer | Ibrance | $274 | 11 payments
|
| Dova Pharmaceuticals | Doptelet | $87 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | None | $71 | 4 payments
|
| GlaxoSmithKline | Blenrep | $68 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $54 | 2 payments
|
| Array Biopharma | Braftovi | $52 | 2 payments
|
| Seagen | Adcetris | $43 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $38 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $36 | 2 payments
|
| Janssen Biotech | Darzalex | $30 | 1 payment
|
| Genzyme | Sarclisa | $24 | 1 payment
|
| Astellas Pharma US | Padcev | $21 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $19 | 1 payment
|
| Lilly USA | Cyramza | $18 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $15 | 1 payment
|
2019: $4,510
| AstraZeneca Pharmaceuticals LP | Imfinzi | $2,617 | 7 payments
|
| Novartis Pharmaceuticals | Kisqali | $990 | 12 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $210 | 11 payments
|
| Insmed | Arikayce | $125 | 1 payment
|
| Alexion Pharmaceuticals | None | $125 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $94 | 5 payments
|
| Janssen Biotech | Darzalex | $63 | 2 payments
|
| Foundation Medicine | Foundationone | $55 | 2 payments
|
| Lilly USA | Verzenio | $52 | 3 payments
|
| Rigel Pharmaceuticals | Tavalisse | $49 | 2 payments
|
| Pfizer | Talzenna | $46 | 2 payments
|
| Seattle Genetics | Adcetris | $22 | 1 payment
|
| Celgene | Revlimid | $17 | 1 payment
|
| Amgen | Kyprolis | $17 | 1 payment
|
| Puma Biotechnology | Nerlynx | $17 | 1 payment
|
| Clovis Oncology | Rubraca | $12 | 1 payment
|
Checkups this office reported
5 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 100%That's most of the people this applied to. | 445 |
| Closing the Referral Loop: Receipt of Specialist ReportAs Medicare defines this measure | 100% | 66 |
| Medications listed in the chartVisits where the current medication list was documented | 100%That's most of the people this applied to. | 1,365 |
| Screening for High Blood Pressure and Follow-Up DocumentedAs Medicare defines this measure | 100% | 1,140 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 100%That's most of the people this applied to. | 596 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Provide 24/7 Access to MIPS Eligible Clinicians or Groups Who Have Real-Time Access to Patient's Medical Record
Professional record
- NPI
- 1831488337
- Licence
- CA A128450California A128450: Current · expires 2027-06-30
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Student in a training program (390200000X)
- Mailing address
- 200 Jose Figueres Ave, Suite 245, San Jose, CA, 95116
- NPI first listed
- 2011-04-05
- NPI last updated
- 2017-05-11
This is when the NPI record was last certified, not a medical board exam.